Skip to main content

Table 2 Status of anticoagulant therapy among patients with NVAF at the different risk levels of stroke and bleeding

From: Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study

 

NOAC, n(%)

Warfarin, n(%)

Aspirin, n(%)

No medication, n(%)

CHA2DS2-VASc

 Male: 0~2; female: 0~1

18 (11.2)

38 (23.6)

37 (23.0)

68 (42.2)

 Male ≥3; female ≥2

48 (11.1)

107 (24.8)

132 (30.5)

145 (33.6)

HAS-BLED

  < 3

56 (10.5)

131 (24.7)

152 (28.6)

192 (36.2)

  ≥ 3

10 (16.1)

14 (22.6)

17 (27.4)

21 (33.9)

  1. Abbreviations: CHA2DS2-VASc Congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65–74 years, sex category (female), HAS-BLED Hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly (age > 65 years), drugs and/or alcohol concomitantly, NOAC Non-vitamin K antagonist oral anticoagulant, NVAF Non-valvular atrial fibrillation